Amgen to offer $6 billion of senior notes in four tranches

By Sheri Kasprzak

New York, Nov. 7 - Amgen Inc. announced plans Monday to price $6 billion of senior notes in four tranches, said a market source familiar with the sale.

The offering includes $1 billion of three-year notes, $1 billion of five-year notes, $1.75 billion of 10-year notes and $2.25 billion of 30-year notes.

The joint bookrunners for the sale are Bank of America Merrill Lynch, Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Citigroup Global Markets Inc.

Proceeds from the notes (A3/A+/A+) will be used for the company's stock repurchase program and for general corporate purposes.

Located in Thousand Oaks, Calif., Amgen manufactures and markets human therapeutics based on advances in cellular and molecular biology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.